GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Days Sales Outstanding

ACHV (Achieve Life Sciences) Days Sales Outstanding : 0.00 (As of Dec. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Days Sales Outstanding?

Achieve Life Sciences's average Accounts Receivable for the three months ended in Dec. 2024 was $0.00 Mil. Achieve Life Sciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Achieve Life Sciences's Days Sales Outstanding or its related term are showing as below:

During the past 13 years, Achieve Life Sciences's highest Days Sales Outstanding was 57.18. The lowest was 57.18. And the median was 57.18.

ACHV's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 71.28
* Ranked among companies with meaningful Days Sales Outstanding only.

Achieve Life Sciences's Days Sales Outstanding stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Achieve Life Sciences Days Sales Outstanding Historical Data

The historical data trend for Achieve Life Sciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Days Sales Outstanding Chart

Achieve Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Achieve Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achieve Life Sciences's Days Sales Outstanding

For the Biotechnology subindustry, Achieve Life Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Days Sales Outstanding falls into.


;
;

Achieve Life Sciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Achieve Life Sciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Achieve Life Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences  (NAS:ACHV) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Achieve Life Sciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Days Sales Outstanding
Comparable Companies
MIST COYA VTYX IMUX ELTX TELO CABA ACOG ASBP ATOS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
SP4P:Germany SP4P:Germany
Address
22722 29th Drive SE, Suite 1000, Bothell, WA, USA, 98021
Website
https://www.achievelifesciences.com
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Executives
Richard Alistair Stewart director, officer: President & CEO 19820 NORTH CREEK PARKWAY, SUITE 201, BOTHELL WA 98011
John Bencich officer: CFO and PFO 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King director 91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc 10 percent owner C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn 10 percent owner C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc 10 percent owner 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb 10 percent owner 2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p. 10 percent owner C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p. 10 percent owner 2770 SAND HILL ROAD, MENLO PARK CA 94025